Associated Papers
Pirtobrutinib targets BTK C481S in ibrutinib-resistant CLL but second-site BTK mutations lead to resistance.
Naeem A et al.
Blood Advances, 2023
36287227 (PubMed )
Supplement: BLOODA_ADV-2022-008447-mmc1.xlsx › Table_S3
The molecular-genetic basis of functional hyperandrogenism and the polycystic ovary syndrome.
Escobar-Morreale HF et al.
Endocrine Reviews, 2005
Select a paper to view details